close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.780 -0.040 (-1.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,190,985
Open 2.800
Bid (Size) 2.790 (600)
Ask (Size) 2.900 (200)
Prev. Close 2.820
Today's Range 2.630 - 2.910
52wk Range 1.660 - 4.537
Shares Outstanding 81,632,619
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? ↗
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026. 
Via The Motley Fool
News headline image
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
From Editas Medicine, Inc.
Via GlobeNewswire

Performance

YTD
+35.6%
+35.6%
1 Month
-7.3%
-7.3%
3 Month
+36.3%
+36.3%
6 Month
+31.8%
+31.8%
1 Year
+57.1%
+57.1%

More News

Read More
News headline image
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
From Editas Medicine, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
News headline image
Editas Medicine Announces Proposed Public Offering
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces First Quarter 2026 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Is Editas Medicine Going to $0? ↗
Via The Motley Fool
News headline image
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas (EDIT) Q2 2024 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Editas Medicine Inc (NASDAQ:EDIT) Beats Q3 2025 Estimates and Provides Key Pipeline Update ↗
Via Chartmill
News headline image
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
News headline image
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗
Via Benzinga
News headline image
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Inc (NASDAQ:EDIT) Shows High Growth Momentum and Strong Technical Trend ↗
Via Chartmill
News headline image
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗
Via Benzinga
News headline image
Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
Via Benzinga
News headline image
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
From Editas Medicine, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Editas Medicine, Inc. - Common Stock publicly traded?
Yes, Editas Medicine, Inc. - Common Stock is publicly traded.
What exchange does Editas Medicine, Inc. - Common Stock trade on?
Editas Medicine, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Editas Medicine, Inc. - Common Stock?
The ticker symbol for Editas Medicine, Inc. - Common Stock is EDIT on the Nasdaq Stock Market
What is the current price of Editas Medicine, Inc. - Common Stock?
The current price of Editas Medicine, Inc. - Common Stock is 2.780
When was Editas Medicine, Inc. - Common Stock last traded?
The last trade of Editas Medicine, Inc. - Common Stock was at 06/03/26 04:00 PM ET
What is the market capitalization of Editas Medicine, Inc. - Common Stock?
The market capitalization of Editas Medicine, Inc. - Common Stock is 226.94M
How many shares of Editas Medicine, Inc. - Common Stock are outstanding?
Editas Medicine, Inc. - Common Stock has 227M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today